News Related to Hypotension

Related coverage linked through entity extraction aliases.

FDA Approves Monthly Dosing Schedule for Rybrevant Faspro in EGFR-Mutated Lung Cancer

Dec 18, 2025

The FDA approved a once-monthly dosing schedule for Rybrevant Faspro with Lazcluze for first-line treatment of EGFR-mutated advanced NSCLC, reducing clinic visits while maintaining safety and efficacy established with bi-weekly dosing.

FDA Approves Zycubo for Menkes Disease After Manufacturing Issue Resolution

Oct 01, 2025

The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.